Riskpilot← Back to searchSign inGet full accessResistance Oncology ApS
APSActiveCVR 36945125Amaliegade 13, 3.Wholesale of pharmaceutical and medical goods · NACE 4646Est. 20151 employees
Revenue 2024
DKK -16K
-25% vs 2023
EBITDA margin
100.0%
+25% vs 2023
Equity ratio
68.7%
Financial strength
Net profit 2024
DKK -29K
-32% vs 2023
| Revenue | DKK -16K | -25% |
| EBITDA | DKK -16K | +25% |
| Net profit | DKK -29K | -32% |
| Total assets | DKK 448K | +810% |
| Equity | DKK 307K | +585% |
| Employees | 1 | — |
Legal name
Resistance Oncology ApS
CVR number
36945125
Legal form
Anpartsselskab
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
1. juli 2015
Share capital
DKK 51.000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af en direktør.
Company purpose
Selskabets formål er at drive virksomhed med produktion, handel og service inden for life science, hvilket efter direktionens bestemmelse kan ske gennem koncernforbundne selskaber samt hermed beslægtet aktivitet
Address
Amaliegade 13, 3.
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | -1.666 | 51 | -14 | 14 | -9 | -10 | -12 | -21 | -16 |
| Staff expenses | -1.772 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBITDA | -3.438 | 51 | -14 | 14 | -9 | -10 | -12 | -21 | -16 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | -3.438 | 51 | -14 | 14 | -9 | -10 | -12 | -21 | -16 |
| Net financials | -176 | 1.097 | -2 | -1 | -0 | -1 | -1 | -7 | -19 |
| Profit before tax | -3.614 | 1.149 | -16 | 13 | -10 | -11 | -13 | -28 | -34 |
| Tax | -793 | 1 | -4 | 3 | -2 | -2 | -3 | -6 | -5 |
| Net profit | -2.821 | 1.147 | -13 | 10 | -8 | -9 | -10 | -22 | -29 |
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Total assets | 793 | 52 | 43 | 8 | 6 | 6 | 7 | 49 | 448 |
| Equity | -2.771 | -12 | -25 | -15 | -23 | -31 | -41 | -63 | 307 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 3.564 | 64 | 68 | 23 | 29 | 37 | 48 | 113 | 140 |
| Total debt | 3.564 | 64 | 68 | 23 | 29 | 37 | 48 | 113 | 140 |
EBITDA margin
-1571200.0%
This company
15.8%
Market median
-9944404% vs market
20162024
Equity ratio
68.7%
This company
38.2%
Market median
+80% vs market
20162024
Return on equity
-9.4%
This company
18.4%
Market median
-151% vs market
20162024
Net profit margin
-2904800.0%
This company
8.1%
Market median
-35861828% vs market
20162024
Asset turnover
-0.04×
This company
1.12×
Market median
-104% vs market
20162024
Debt / equity
0.46×
This company
0.62×
Market median
+26% vs market
20162024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2015-07-01 – 2016-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
NA Management | Management | 2022 | — | — |
JP Management | Management | 2016 | — | — |
PA Chief Executive Officer | Chief Executive Officer | 2015 | — | — |
MF Management | Management | 2015 | — | — |
KP Management | Management | 2022 | — | — |
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Pasternak Holding ApS | Company | 50.0% | 50.0% | 2026 |
TIMPCO NB ApS | Company | 25.0% | 25.0% | 2025 |
Alexander Meier Holding ApS | Company | 5.0% | 5.0% | 2025 |
CORTRIS ApS | Company | 100.0% | 100.0% | 2015 |
PASTERNAK JØRGENSEN HOLDING ApS | Company | 50.0% | 50.0% | 2025 |
| Individual | 5.0% | 5.0% | 2015 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
TIMPCO NB ApS
Resistance Oncology ApS Board members of Resistance Oncology ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Nils Aage Brünner | Management | 0 companies |
| Jørgen Peter Jørgensen | Management | 0 companies |
| Peter Andreas Stakemann | Chief Executive Officer | 0 companies |
| Morten Fadum Nissen | Management | 0 companies |
| Kasper Pasternak Jørgensen | Management | 0 companies |